Nomenclature
Short Name:
SCYL2
Full Name:
Similar to mouse D10Ertd802e protein
Alias:
- Coated vesicle-associated kinase of 104 kDa
- KIAA1360
- SCY1-like protein 2
Classification
Type:
Protein-serine/threonine kinase
Group:
Other
Family:
SCY1
SubFamily:
NA
Structure
Mol. Mass (Da):
103,709
# Amino Acids:
929
# mRNA Isoforms:
1
mRNA Isoforms:
103,709 Da (929 AA; Q6P3W7)
4D Structure:
Interacts with clathrin and AP2B1; the interaction mediates the association with the AP-2 complex.
1D Structure:
Subfamily Alignment
Domain Distribution:
| Start | End | Domain |
|---|---|---|
| 32 | 327 | Pkinase |
| 443 | 479 | HEAT |
| 486 | 523 | HEAT |
| 599 | 619 | Coiled-coil |
| 673 | 699 | Coiled-coil |
Post-translation Modifications
For detailed information on phosphorylation of this kinase go to PhosphoNET
Acetylated:
K9.
Methylated:
K688.
Serine phosphorylated:
S277, S350, S622, S677, S751, S759, S857.
Threonine phosphorylated:
T438, T440, T708, T712, T737, T760, T810.
Tyrosine phosphorylated:
Y275, Y795.
Distribution
Based on gene microarray analysis from the NCBI
Human Tissue Distribution
% Max Expression:
Mean Expression:
Number of Samples:
Standard Deviation:
% Max Expression:
Mean Expression:
Number of Samples:
Standard Deviation:
72
1489
28
1350
2
36
13
39
15
304
11
269
19
392
105
694
43
893
37
697
4
74
55
81
11
223
38
180
44
904
34
2027
11
228
13
274
8
174
86
121
7
139
26
138
35
728
101
612
7
135
22
146
1.4
28
9
31
9
188
24
322
3
70
17
45
7
149
156
104
10
197
19
263
10
200
86
371
43
895
115
730
6
133
23
158
9
179
25
206
15
305
12
283
7
155
19
205
10
200
23
237
37
760
71
658
7
142
28
195
6
133
19
160
7
150
19
179
8
176
42
113
54
1128
18
743
100
2073
31
3711
9
178
79
375
56
1155
78
717
10
207
48
315
Evolution
Species Conservation
PhosphoNET % Identity:
PhosphoNET % Similarity:
Homologene %
Identity:
PhosphoNET % Identity:
PhosphoNET % Similarity:
Homologene %
Identity:
100
100
100
99.8
99.8
0
99.3
99.7
-
-
-
97
-
-
-
97.1
98.3
97
-
-
-
93
96.7
93
94
96.8
94
-
-
-
84
88.2
-
68
74.1
84
-
-
79
70.7
82.3
74
-
-
-
40.3
60.4
52
39.4
56.8
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
26
-
-
30
-
-
23
-
-
25
For a wider analysis go to PhosphoNET Evolution in PhosphoNET
Binding Proteins
Examples of known interacting proteins
hiddentext
| No. | Name – UniProt ID |
|---|---|
| 1 | CLTC - Q00610 |
| 2 | ZFYVE9 - O95405 |
Regulation
Activation:
NA
Inhibition:
NA
Synthesis:
NA
Degradation:
NA
Protein Kinase Specificity
Matrix of observed frequency (%) of amino acids in aligned protein substrate phosphosites
Matrix Type:
Predicted from the application of the Kinexus Kinase Substrate Predictor Version 2.0 algorithm, which was trained with over 10,000 kinase-protein substrate pairs and 8,000 kinase-peptide substrate pairs.
Domain #:
1
Disease Linkage
Gene Expression in Cancers:
TranscriptoNET (www.transcriptonet.ca) analysis with mRNA expression data retrieved from the National Center for Biotechnology Information's Gene Expression Omnibus (GEO) database, which was normalized against 60 abundantly and commonly found proteins, indicated altered expression for this protein kinase as shown here as the percent change from normal tissue controls (%CFC) as supported with the Student T-test in the following types of human cancers: Clear cell renal cell carcinomas (cRCC) stage I (%CFC= +415, p<0.0001); and Uterine leiomyomas from fibroids (%CFC= -48, p<0.039). The COSMIC website notes an up-regulated expression score for SCYL2 in diverse human cancers of 360, which is 0.8-fold of the average score of 462 for the human protein kinases. The down-regulated expression score of 109 for this protein kinase in human cancers was 1.8-fold of the average score of 60 for the human protein kinases.
Mutagenesis Experiments:
Insertional mutagenesis studies in mice have not yet revealed a role for this protein kinase in mouse cancer oncogenesis.
Mutation Rate in All Cancers:
Percent mutation rates per 100 amino acids length in human cancers: 0.06 % in 24726 diverse cancer specimens. This rate is only -17 % lower than the average rate of 0.075 % calculated for human protein kinases in general.
Mutation Rate in Specific Cancers:
Highest percent mutation rates per 100 amino acids length in human cancers: 0.26 % in 1270 large intestine cancers tested; 0.23 % in 603 endometrium cancers tested; 0.18 % in 1634 lung cancers tested; 0.15 % in 864 skin cancers tested; 0.12 % in 1276 kidney cancers tested; 0.09 % in 589 stomach cancers tested; 0.07 % in 1316 breast cancers tested; 0.05 % in 833 ovary cancers tested; 0.05 % in 1512 liver cancers tested; 0.04 % in 548 urinary tract cancers tested; 0.04 % in 273 cervix cancers tested; 0.03 % in 710 oesophagus cancers tested; 0.03 % in 382 soft tissue cancers tested; 0.03 % in 2103 central nervous system cancers tested; 0.03 % in 1459 pancreas cancers tested; 0.02 % in 942 upper aerodigestive tract cancers tested; 0.02 % in 558 thyroid cancers tested; 0.01 % in 881 prostate cancers tested; 0.01 % in 2009 haematopoietic and lymphoid cancers tested.
Frequency of Mutated Sites:
Most frequent mutations with the number of reports indicated in brackets: Q715H (10); Q859H (4); Q859R (2); V788I (3).
Comments:
Only 4 deletions, 2 insertions, and no complex mutations are noted on the COSMIC website.